ANI Pharmaceuticals (NASDAQ:ANIP) Shares Gap Down – Here’s Why

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)’s share price gapped down prior to trading on Friday . The stock had previously closed at $82.63, but opened at $77.09. ANI Pharmaceuticals shares last traded at $76.13, with a volume of 142,181 shares traded.

Trending Headlines about ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Second-quarter adjusted EPS was $2.21, above the roughly $2.01-$2.04 analyst estimates and up from $1.80 a year earlier. Revenue reached $266.0 million, exceeding estimates near $260 million and increasing 25.9% year over year. ANI Pharmaceuticals Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Cortrophin Gel revenue rose 43.5% to $117.1 million, while adjusted EBITDA increased 32.4% to $71.6 million. Management also reported encouraging early demand from its expansion into gout treatment, with the expanded sales organization fully operational by the end of June. ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
• Positive Sentiment: ANI reaffirmed 2026 total revenue guidance of $1.08 billion-$1.14 billion and adjusted EBITDA guidance of $285 million-$300 million. Adjusted EPS guidance of $9.19-$9.69 is also above the current consensus estimate of $9.10, and the company has authorization to repurchase up to $100 million of stock. Compared to Estimates, ANI Q2 Earnings: A Look at Key Metrics
• Neutral Sentiment: Generics revenue grew 9.7% to $99.1 million, supported by new launches, and the company has introduced 12 generic products year to date. ANI ended the quarter with $360.2 million in cash and generated $115 million in operating cash flow during the first half.
• Negative Sentiment: Management reduced 2026 Cortrophin Gel revenue guidance to $520 million-$540 million from $540 million-$575 million. Although the new range still implies 50%-55% annual growth, the cut likely disappointed investors counting on faster commercialization of the gout opportunity.
• Negative Sentiment: GAAP gross margin declined to 62.4% from 64.7%, partly because of a higher mix of royalty-bearing products and the non-recurrence of prior-year revenue. ILUVIEN revenue fell 16.1% to $18.7 million, while Brands revenue declined 10.5%.

Wall Street Analyst Weigh In

Several equities analysts recently commented on ANIP shares. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Guggenheim reissued a “buy” rating and issued a $124.00 price target on shares of ANI Pharmaceuticals in a report on Friday, July 10th. Weiss Ratings raised shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, June 23rd. Canaccord Genuity Group started coverage on ANI Pharmaceuticals in a research report on Thursday, July 16th. They issued a “hold” rating and a $91.00 price objective on the stock. Finally, Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Six equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $105.00.

ANI Pharmaceuticals Price Performance

The firm has a market capitalization of $1.79 billion, a PE ratio of 19.70 and a beta of 0.44. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. The business’s 50 day moving average is $81.03 and its two-hundred day moving average is $79.38.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. The business had revenue of $266.04 million during the quarter, compared to analysts’ expectations of $260.13 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The business’s quarterly revenue was up 25.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, research analysts anticipate that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current year.

Insider Activity at ANI Pharmaceuticals

In related news, SVP Thomas Andrew Rowland sold 459 shares of the company’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $79.21, for a total value of $36,357.39. Following the completion of the transaction, the senior vice president directly owned 38,271 shares in the company, valued at approximately $3,031,445.91. The trade was a 1.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Stephen P. Carey sold 2,850 shares of the stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $81.36, for a total value of $231,876.00. Following the completion of the transaction, the chief financial officer directly owned 174,693 shares in the company, valued at approximately $14,213,022.48. This represents a 1.61% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 88,029 shares of company stock worth $6,954,472 in the last three months. 8.10% of the stock is owned by insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Institutional investors have recently modified their holdings of the company. KBC Group NV purchased a new position in shares of ANI Pharmaceuticals during the 1st quarter valued at about $28,000. Advisors Asset Management Inc. purchased a new stake in ANI Pharmaceuticals in the first quarter worth approximately $28,000. Hantz Financial Services Inc. boosted its stake in ANI Pharmaceuticals by 70.3% in the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after buying an additional 249 shares in the last quarter. Kemnay Advisory Services Inc. bought a new position in ANI Pharmaceuticals during the fourth quarter valued at approximately $48,000. Finally, State of Wyoming bought a new position in ANI Pharmaceuticals during the second quarter valued at approximately $50,000. 76.05% of the stock is currently owned by institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.